Trial Profile
Multicenter, Open-Label, Randomized Phase III Trial for Administration of Zoledronate to Breast Cancer Metastatic Patients With Non-Symptomatic Bone Lesions
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Apr 2019
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 14 Dec 2006 Status change
- 02 Dec 2005 New trial record.